title: Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
authors.forename: P A
authors.initials: PA
authors.lastname: Thompson
authors.forename: H M
authors.initials: HM
authors.lastname: Prince
authors.forename: J F
authors.initials: JF
authors.lastname: Seymour
authors.forename: D
authors.initials: D
authors.lastname: Ritchie
authors.forename: K
authors.initials: K
authors.lastname: Stokes
authors.forename: K
authors.initials: K
authors.lastname: Burbury
authors.forename: M
authors.initials: M
authors.lastname: Wolf
authors.forename: S
authors.initials: S
authors.lastname: Peinert
authors.forename: T
authors.initials: T
authors.lastname: Joyce
authors.forename: S J
authors.initials: SJ
authors.lastname: Harrison
mesh_terms: D000328:Adult; D000368:Aged; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery*; D011719:Pyrazines / Q000008:administration & dosage*; D012008:Recurrence; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D008558:Melphalan